Website is under construction and will be updated soon

Building a robust oncology portfolio to address significant unmet needs via the targeting of CSF1R:

  • Minimal residual disease (MRD) in Colorectal Cancer that will progress to metastasis if left untreated
  • Tenosynovial giant cell tumor (TGCT), a locally aggressive joint sarcoma, that can benefit from a novel local administration, to expand physician treatment options
  • Acute Myeloid Leukemia (AML) via an antibody drug conjugate (ADC) format

R&D pipeline – leveraging clinically-validated CSF1R MOA in highly differentiated oncology programs with large commercial opportunities

TAM* = Total Addressable Market in the US and EU

Latest news

Dec 10, 2024

AmMax Bio and MD Anderson Announce Agreements to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease

Read more

Sep 27, 2024

AmMax Bio to Present at the Oppenheimer Healthcare Private Company Showcase

Read more
logo_AmMax_white

AmMax Bio Inc.

Redwood City, CA, USA

Corp Dev & Partnering

Laura Zhu, Ph.D., MBA

Chief Business Officer

Larry Hsu, PhD

Chief Executive Officer

Investor Relations

Andrew Sauter

Chief Financial Officer

©2024 AmMax Bio Inc.